StockNews.com cut shares of Royalty Pharma (NASDAQ:RPRX – Get Rating) from a buy rating to a hold rating in a research note published on Thursday morning. RPRX has been the subject of several other reports. UBS Group dropped their price target on Royalty Pharma from $51.00 to $48.00 and set a buy rating for the […]
Related Keywords
United States , Marshall Urist , Roryb Riggs , Royalty Pharma Company Profile , Blackrock Inc , Morgan Stanley , Securities Exchange Commission , Jpmorgan Chase Co , Baillie Gifford Co , Vanguard Group Inc , Royalty Pharma , Get Rating , Moderate Buy , Exchange Commission , Director Rory , State Street Corp , Street Corp , Royalty Pharma Daily , Nasdaq Rprx , Rprx , Finance , 76028h20 , Downgrade , Stocknews Com ,
comparemela.com © 2020. All Rights Reserved.